CytomX Therapeutics develops cancer treatments using its PROBODY masked biologics platform. It last closed at $1.94 on Nov 17, down 2.27% on the day. In the past 30 days there were 1 dark pool print totaling $254K, the largest $254K.
Only 1 firm rated CTMX in the past 90 days, not enough for a consensus
Average 12-month target
$12.00
▲ 518.6% upside
Based on 1 analyst who set a price target on CTMX in the past 90 days. The average target is $12.00, with a high of $12.00 and a low of $12.00, compared with the last close of $1.94.
Low $12.00Avg $12.00High $12.00
Blue marker: last close $1.94
Highest target$12.00
Average target$12.00
Lowest target$12.00
Latest rating changes
WedbushMaintained
Nov 6Buy$12
JP MorganTarget lowered
Aug 13Buy$12 → $11
GuggenheimMaintained
Aug 10Buy$14
JP MorganUpgrade
Mar 16Buy$12
Date
Firm
Action
Rating
Price target
Nov 6
Wedbush
Maintained
Buy
$12
Aug 13
JP Morgan
Target lowered
Buy
$12 → $11
Aug 10
Guggenheim
Maintained
Buy
$14
Mar 16
JP Morgan
Upgrade
Buy
$12
Loading…
Technical Analysis
CTMX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 13% below its 20 day and 29% below its 50 day average. It is 89% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $1.91, and the nearest resistance the Pivot at $1.95.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.5%/day
Key levels
$8.2152 week high+323.2%
$3.67200 day average+89.2%
$2.99100 day average+54.1%
$2.5050 day average+28.9%
$2.42Swing high (Oct 29)+24.7%
$2.1920 day average+12.9%
$1.98Pivot R1+2.1%
$1.95Pivot+0.5%
$1.94Last close
$1.91Pivot S1−1.5%
$1.9052 week low−2.1%
$1.90Swing low (Nov 10)−2.1%
Indicators
RSI (14)
36.17
Weak, oversold below 30
Neutral
MACD
-0.15
Below its signal line
Bearish
Stochastic
17.0
Near the bottom of its range
Oversold
ADX (14)
25.2
Trending down
Williams %R
-92.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-135.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−11.0%
Change over 10 sessions
Bearish
ATR (14)
$0.16
Typical daily range, 8.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityNormal, 21.7%/day
Key levels
$8.2152 week high+323.2%
$3.67200 day average+89.2%
$2.99100 day average+54.1%
$2.5050 day average+28.9%
$2.42Swing high (Oct 29)+24.7%
$2.1920 day average+12.9%
$1.98Pivot R1+2.1%
$1.95Pivot+0.5%
$1.94Last close
$1.91Pivot S1−1.5%
$1.9052 week low−2.1%
$1.90Swing low (Nov 10)−2.1%
Indicators
RSI (14)
29.67
Oversold below 30
Oversold
MACD
-0.45
Below its signal line
Bearish
Stochastic
4.5
Near the bottom of its range
Oversold
ADX (14)
21.3
Weak trend
Williams %R
-98.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-124.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−41.0%
Change over 10 sessions
Bearish
ATR (14)
$0.42
Typical daily range, 21.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CTMX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CTMX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow CTMX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CTMX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CTMX is in one of them and how their past CTMX trades turned out.
CytomX Therapeutics is a biopharmaceutical company based in South San Francisco, California, that develops cancer treatments. It uses its PROBODY platform to build masked biologic therapies, which are designed to bind more selectively within tumors and limit effects on healthy tissue. Its most advanced candidate, Varsetatug Masetecan, is an antibody drug conjugate being studied in colorectal cancer, with plans to test it in other solid tumors. The company's therapies are aimed at cancer patients.